Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abemaciclib plus tamoxifen versus abemaciclib alone in previously treated HR-positive, HER2-negative metastatic breast cancer
2023-507175-22-00Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Sep 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in breast cancer comparing Abemaciclib plus tamoxifen with Abemaciclib alone (2 arms). Primary endpoint: Progression-free survival. Started Sep 2016; status: completed.
02
Drugs
abemaciclibtamoxifen
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2023-507175-22-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-507175-22-00.